{
  "id": 16225067,
  "title": "GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)",
  "url": "https://urgent.news/2026/10/23/glp-1-muscle-loss-the-next-battleground-in-obesity-treatment-part-2",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-23T08:10:24.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/podcast/glp-1-muscle-loss-the-next-battleground-in-obesity-treatment-part-2-of-3/"
  },
  "original_language": "en",
  "account": null,
  "summary": "In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants. The post GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3) appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}